Not logged inClonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies
Rescigno, P.; Mahmood, A.; Lagonera, M.; Bashir, S.; Haris, N.; Mohammed, A.; Shaheen, A.; Gautam, A.; Taylor, E.; Smith, J.; Rae, S.; MacCormack, C.; Hogarth, L.; Oing, C.; Plummer, R.; Greystoke, A. .png)
Share.png)
SaveSocial determinants of health inequalities in early phase clinical trials in Northern EnglandRae, S.; Shaya, S.; Taylor, E.; Hoben, J.; Oluwashegun, D.; Lowe, H.; Haris, N.; Bashir, S.; Oing, C.; Krebs, M. G.; Thistlethwaite, F. C.; Carter, L.; Cook, N.; Greystoke, A.; Graham, D. M.; Plummer, R. Share Save Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumorsCook, Natalie; Blagden, Sarah; Lopez, Juanita; Sarker, Debashis; Greystoke, Alastair; Haris, Noor Md; Kazmi, Farasat; Anam, Kaiser; Franco, Ana Ortego; Pihlak, Rille; Goodwin, Louise; Wilson, David; Phillips, Caroline; Robertson, Jane; Timmis, Helen; Tilston, Craig; Woodcock, Simon A.; Plummer, Ruth Share Save Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial FinderRae, S. C. A.; Plummer, E.; Fitzgerald, L.; Hogarth, L.; Bridgewood, A.; Brown-Schofield, L.; Graham, J.; Drew, Y.; Haris, N.; Bashir, S.; Plummer, R.; Greystoke, A. Share Save A first-in-human study of NUC-7738, a ProTide transformation of 3′-deoxyadenosine, in patients with advanced solid tumours (NuTide:701)Blagden, S.; Haris, N. M.; Boh, Z.; Kazmi, F.; Aroldi, F.; Myers, M.; Symeonides, S. N.; Plummer, R. Share Save The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM)Tiu, C.; Tzankov, A.; Plummer, R.; Rulach, R.; Vivanco, I.; Mulholland, P. J.; Gurel, B.; Figueiredo, I.; Haris, N. Md.; Anderson, S.; Bachmann, F.; Engelhardt, M.; Kaindl, T.; Lane, H.; Litherland, K.; Pognan, C.; Berezowska, S.; Evans, J.; Kristeleit, R.; Lopez, J. S. Share Save SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line settingGreystoke, Alastair; Steele, Nicola; Arkenau, Hendrik-Tobias; Blackhall, Fiona; Haris, Noor Md; Lindsay, Colin R.; Califano, Raffaele; Voskoboynik, Mark; Summers, Yvonne; So, Karen; Ghiorghiu, Dana; Dymond, Angela W.; Hossack, Stuart; Plummer, Ruth; Dean, Emma Share Save SELECT-3: A phase I study of selumetinib in combination with platinumdoublet chemotherapy for advanced NSCLC in the first-line settingDean, E.; Steele, N.; Arkenau, H-T.; Blackhall, F.; Haris, N. M.; Lindsay, C.; Rafii, S.; Califano, R.; Plummer, R.; Voskoboynik, M.; Summers, Y. J.; Ghiorghiu, D.; Dymond, A.; So, K.; Greystoke, A. Share Save A phase I dose escalation study to assess the safety tolerability and pharmacokinetics of ETS2101 in patients (pts) with advanced solid tumoursPlummer, R.; Anthoney, A.; Evans, J.; Haris, N.; D'Archangelo, M.; Slater, S.; Campbell, S.; Brindley, C.; Self, S.; McKeown, P.; Lavin, S.; Hynes, D.; Flores, M. V.; Pedret-Dunn, A.; Laffranchi, B. Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
